Investment Thesis
Aldeyra Therapeutics is a pre-revenue pharmaceutical company with strong cash position ($65M) and improving operational efficiency (39% YoY loss reduction), but faces fundamental risks from zero revenue generation and ongoing annual cash burn of $5.1M with unclear commercialization timeline. While the 12+ year cash runway provides substantial cushion, the absence of revenue and negative profitability metrics present significant fundamental headwinds.
Strengths
- Exceptional cash position of $65M with 2.72x current ratio, providing 12+ years of operating runway at current burn rates
- Net losses declining meaningfully (+39.4% YoY), indicating improving operational efficiency
- Conservative capital structure with 0.36x debt-to-equity and manageable $15.3M long-term debt burden
Risks
- Complete absence of revenue generation - entirely pre-commercial pharmaceutical development stage
- Negative operating cash flow of -$5.1M annually with no profitability path demonstrated
- Pre-revenue status creates binary outcomes dependent on pipeline success; no commercial validation of drug efficacy or market demand
Key Metrics to Watch
- First revenue generation and product commercialization timeline
- Operating cash burn rate and cash runway extension through financing or partnerships
- Clinical trial progress and regulatory approval milestones for pipeline candidates
Financial Metrics
Revenue
N/A
Net Income
-3.5M
EPS (Diluted)
$-0.06
Free Cash Flow
-5.1M
Total Assets
66.5M
Cash
65.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-8.2%
ROA
-5.2%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
2.72x
Quick Ratio
2.72x
Debt/Equity
0.36x
Debt/Assets
36.6%
Interest Coverage
-3.63x
Long-term Debt
15.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:34:37.394016 |
Data as of: 2026-03-31 |
Powered by Claude AI